NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATIONS OR OTHER MEASURES NOT STIPULATED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

aXichem AB (publ) ("aXichem" or the "Company") aXichem AB (publ) ("aXichem" or the "Company") today presents the outcome of the rights issue, announced on February 23, 2023, with the last day for subscription on March 22, 2023 (the “Rights Issue"). A total of 3,608,646 shares, corresponding to approximately 51 percent of the Rights Issue, were subscribed with the support of subscription rights. In addition, 1,352,043shares were subscribed without the support of subscription rights, corresponding to approximately 19 percent of the Rights Issue, of which approximately 12 percent of the Rights Issue refers to subscription attributable to entered guarantee commitments. A total of 4,960,689 shares were subscribed, thus the Rights Issue was subscribed to 70 percent.

Through the Rights Issue, aXichem will receive approximately 34,7 million SEK before issue costs. Through the Rights Issue, the number of shares in aXichem increases by 4,960,689 shares from 16,535,636 shares to 21,496,325 shares and the share capital increases by 992,137.80 SEK from SEK 3,307,127.20 to 4,299,265 SEK.

Allotment of shares subscribed without the support of subscription rights has taken place in accordance with the principles stated in the prospectus drawn up in connection with the rights issue, which was published by the Company on March 3, 2023. Notice of allotment takes place by the sending of a separate settlement note, which is expected to be sent out on or about 24 March 2023. Subscribed and allotted shares must be paid in cash in accordance with the instructions on the settlement note. Shareholders with custodian accounts will receive notification of allotment in accordance with each account holding bank’s routines.

Those who subscribed for shares in the rights issue will receive BTA (paid subscribed share). Trading in BTA takes place on Nasdaq First North Growth Market until the issue has been registered with the Swedish Companies Registration Office. BTA will then be converted into ordinary shares.

Financial advisers, legal advisers and issuing agent

Västra Hamnen Corporate Finance AB (publ) acts as financial adviser and Vinge acts as legal adviser to aXichem in connection with the rights issue. Nordic Issuing acts as issuing agent.

The information was submitted, through the agency of the contact person, for publication on March 24, 2023, at 12:00 CET.